CHF Solutions Expands Commercial Presence in the Middle East with Distribution Arrangement for United Arab Emirates

EDEN PRAIRIE, Minn., May 28, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS) today announced the signing of a distribution agreement with Transimed Medical Equipment Co. LLC covering the United Arab Emirates, the first distribution partnership in the Middle East region. The company now has distribution agreements covering 14 countries outside the U.S.

“This partnership demonstrates our continued commitment to make ultrafiltration therapy available for patients throughout the world, as we expand into this new region,” said John Erb, chairman and CEO of CHF Solutions. “Subject to regulatory approval, we look forward to working with Transimed to make the simple, flexible and smart Aquadex SmartFlow system available to patients in the U.A.E suffering from fluid overload due to heart failure, cardiovascular surgery and other critical care conditions.”

“We are very excited to work with CHF Solutions to introduce their state-of-the-art technology to the U.A.E. market,” said Mohammed Zein, CEO of Transimed. “We believe the Aquadex therapy will make a difference in the quality of lives of heart failure patients in the UAE. We look forward to a successful partnership that aims to improve patients’ lives.”

In the United Arab Emirates, over 90,000 patients are treated annually for heart failure at an overall cost of approximately $500 million.¹

About CHF Solutions

CHF Solutions, Inc. (CHFS) is a medical device company dedicated to changing the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on developing, manufacturing and commercializing the Aquadex SmartFlow system for ultrafiltration therapy. CHF Solutions is headquartered in Minneapolis, Minn., with wholly-owned subsidiaries in Australia and Ireland. The company has been listed on the Nasdaq Capital Market since February 2012.

About the Aquadex SmartFlow System

The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.